Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: An international, randomised, open-label, phase 3 trial

EPIC investigators

Research output: Contribution to journalArticlepeer-review

204 Scopus citations

Fingerprint

Dive into the research topics of 'Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: An international, randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences